No Data
No Data
AtriCure, Inc. (NASDAQ:ATRC) Might Not Be As Mispriced As It Looks
There wouldn't be many who think AtriCure, Inc.'s (NASDAQ:ATRC) price-to-sales (or "P/S") ratio of 2.8x is worth a mention when the median P/S for the Medical Equipment industry in the United States
AtriCure to Announce Second Quarter 2024 Financial Results
AtriCure, Inc. ((
Analyst Ratings For AtriCure
AtriCure (NASDAQ:ATRC) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The table below summarizes their recent ratings, show
AtriCure Price Target Maintained With a $40.00/Share by Needham
AtriCure Price Target Maintained With a $40.00/Share by Needham
Express News | Needham Reiterates Buy on AtriCure, Maintains $40 Price Target
AtriCure Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/08/2024 78.17% Needham $40 → $40 Reiterates Buy → Buy 05/02/2024 118.26% Canaccord Genuity $57 → $49 Ma
No Data